21 results about "Dibasic sodium phosphate" patented technology

The invention relates to the technical field of iodide content detection, in particular to a method for determining radiochemical purity and iodine content of sodium iodide capsules for diagnosis by HPLC (High Performance Liquid Chromatography), which comprises the following steps: setting chromatographic conditions, and connecting a radioactive flow detector and an ultraviolet detector in series; preparing a disodium hydrogen phosphate solution, a glucose solution, a vitamin C solution, a first control solution, a potassium iodate solution, a second control solution, a carrier solution, a first sample solution, a second sample solution, a negative control solution and a test solution; and determining the radiochemical purity and iodide content of the first sample solution and the second sample solution in three batches based on the chromatographic conditions and the determination standard. According to the method, test parameters such as capsule sample analysis time, a pretreatment mode and a sample size are optimized, the radiochemical purity of the capsule is accurately determined, and the iodide content is controlled, so that the problem that main components cannot be accurately quantified and potential radioactive impurities cannot be detected by a traditional diagnosis sodium iodide [131I] capsule determination method is solved.

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

The invention discloses a wrapping method and application of core-shell type lysozyme particles, and the method comprises the following steps: dropwise adding a negatively charged polypeptide solution with the pH value of 7.4 + / -0.2 into a lysozyme solution with the pH value of 7.4 + / -0.2 at 2-6 DEG C under the magnetic stirring of 200rpm-400rpm, and forming a lysozyme polypeptide core through electrostatic adsorption; mixing the lysozyme polypeptide nucleus, a calcium chloride solution and a disodium hydrogen phosphate solution under stirring at the temperature of less than or equal to 25 DEG C and at the speed of 200-400 rpm, adjusting the pH value to 8.0 + / -0.1, reacting for 1-4 hours, centrifuging, and discarding supernate to obtain lysozyme polypeptide nucleus-calcium phosphate microcapsules; and mixing the lysozyme polypeptide core-calcium phosphate microcapsules with a chitosan solution with the pH value of 5.5-6.0 at the temperature of less than or equal to 25 DEG C under the stirring of 150-250 rpm to form the core-shell type lysozyme particles. According to the method, low-temperature and low-speed stirring is adopted in the whole process, pH is close to neutral, no organic solvent is needed, and effective wrapping of lysozyme is achieved.

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

The invention discloses a preparation method of a standard substance for analyzing phosphorus components in food, which comprises the following steps: (1) cutting off tendons, tendons, bones, skins and fat from fresh livestock meat or poultry meat, and crushing pure meat to obtain meat paste; (2) weighing a certain amount of meat paste, adding a calculated amount of disodium hydrogen phosphate aqueous solution into the meat paste, mixing, and continuously crushing and stirring until the mixture is uniform; (3) carrying out freeze drying on the standard-added and uniformly-mixed meat paste to obtain meat powder blocks; (4) crushing the meat meal blocks, and collecting freeze-dried powder; screening the freeze-dried powder by using a 60-mesh sieve; (5) detecting the moisture content of the sieved freeze-dried powder, wherein the moisture content is less than 5%; and (6) sub-packaging the freeze-dried powder, sealing the freeze-dried powder into independent packaging units, and performing uniformity test to obtain the phosphorus component analysis standard substance. The phosphorus component analysis standard substance has the advantages of uniform phosphorus content, good short-term and long-term stability and accurate content.

A composition and methods of dosing such tirzepatide composition, comprising a tirzepatide, or a salt thereof at a concentration selected from the group consisting of 2.5 mg / mL, 40 mg / mL, and 50 mg / mL; NaCl; and dibasic sodium phosphate is provided.

The present disclosure provides aqueous formulations comprising hydrocortisone sodium phosphate and monothioglycerol. In some embodiments, the formulations comprise monobasic sodium phosphate, dibasic sodium phosphate, or disodium EDTA. The present disclosure further provides a method of treating a disease or disorder in a subject by administering the aqueous formulation.

The invention discloses a preparation method of a slow-release star anise essential oil microcapsule, which comprises the following steps: standing star anise essential oil in a dark place, taking an upper-layer clarified phase, and carrying out ethanol-assisted emulsification, disodium hydrogen phosphate aqueous solution dispersion, high-speed shearing and ice-water bath cooling to form primary emulsion; sequentially introducing gelatin and Arabic gum to construct a composite membrane, adding modified starch to form a ternary structure, loading polylactic acid, and performing freezing-vacuum drying to form a shell; then adopting glutaraldehyde steam cross-linking to stabilize the network, dispersing with cold water, and curing with sodium carboxymethyl cellulose to obtain a stable dispersion liquid; carrying out particle size grading, ceramic membrane filtration and spray drying to obtain microcapsule powder, finally carrying out surface modification by octadecyltriethoxysilane, and adapting to a vaseline or water-based system. Through step-by-step assembly of multi-component wall materials, low-temperature induction of channel orientation and steam crosslinking, the structural stability is enhanced, surface hydrophobicity is used for regulating and controlling interface behaviors, the microcapsule is endowed with internal mass transfer regulation and control capability, and stable, uniform and long-time release of aroma is realized.

Fexofenadine zwitterionic dihydrate form I of formula (I) Paraben-free aqueous pharmaceutical suspension formulations and uses thereof are provided, including JPEG2026501487000031.jpg4390. In certain embodiments, the formulations include polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

Provided is a paraben-free aqueous pharmaceutical suspension formulation comprising fexofenadine zwitterionic dihydrate Form I of formula (I)and uses thereof. In certain embodiments, the formulation comprises polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.

The invention belongs to the field of collagen extraction, and particularly relates to a preparation method of a high-stability I-type collagen solution for injection and an obtained product. The method is realized by the following steps: firstly, pretreating a type I collagen freeze-dried product; and sequentially adding a sodium hyaluronate mixed solution and a chitosan mixed solution 3, fully and uniformly mixing, and adding a disodium hydrogen phosphate buffer solution to obtain the I-type collagen solution for injection. The preparation method disclosed by the invention is simple and easy to operate, the prepared animal-derived I-type collagen solution for injection is relatively good in uniformity and stability, and the selected components are safe and relatively excellent in effectiveness. The type I collagen and the chitosan have good effects of promoting cell proliferation, migration and repair, and related repair products are sold on the market; the type I collagen and the sodium hyaluronate have a good moisturizing effect; the trehalose component has good moisturizing and anti-oxidation effects, and particularly, the trehalose has excellent characteristics of keeping cell viability and biomacromolecule activity; the mannitol component has a good effect of improving the osmotic pressure molar concentration of the solution, the osmotic pressure of the solution can be basically kept consistent with the osmotic pressure of body fluid in the solution, and side effects such as edema are not prone to occurring.

The invention belongs to the field of stability evaluation of polypeptide bulk drugs, discloses a method for predicting the aggregation trend of tilpoitide based on a dynamic light scattering technology, and aims at solving the problems that an existing polypeptide aggregation detection technology is complex in pretreatment, cannot monitor in real time or is low in detection flux. The method comprises the following steps: dispersing polypeptide in a buffer solution with the pH value of 6.5-8.5, adding diethylene glycol-3-amino propyl ether and N '-(4-methoxy-2, 3, 6-trimethylbenzenesulfonyl)-L-arginine as cosolvents, and performing oscillation on an accelerated shaking table for 2-6 hours to prepare a polypeptide solution; determining aggregation when the particle size is greater than the theoretical size of the polypeptide monomer through dynamic light scattering detection; the buffer solution comprises one of a disodium hydrogen phosphate solution, a sodium chloride solution and a tris (2-chloroethyl) phosphate solution. The method disclosed by the invention can be used for rapidly and nondestructively monitoring the aggregation trend of the polypeptide in real time, further replaces a traditional detection method and intuitively represents the aggregation property of the polypeptide.

The present invention relates to a liquid composition comprising: a polyalkylene oxide-asparaginase at a concentration of 750 IU per mL of the composition; dibasic sodium phosphate at a concentration of 0.5 to 0.6% by weight; monobasic sodium phosphate at a concentration of 0.1 to 0.2% by weight; and sodium chloride at a concentration of 0.8 to 1.0% by weight, wherein the polyalkylene oxide-asparaginase comprises an asparaginase covalently linked to a polyalkylene oxide group that is a polyethylene glycol, wherein the polyalkylene oxide group is covalently linked by a carbamate linker to the asparaginase, wherein the carbamate moiety originates from a succinimidyl carbonate (SC) linker

The present invention relates to a smokeless article for oral delivery comprising a pouch enclosing an oral nicotine delivery (OND) formulation, the OND formulation comprising at least two pH regulators selected from the list of sodium carbonate, sodium hydroxide, calcium lactate, sodium phosphate dibasic, sodium citrate, meglumine, ammonia, ammonium carbonate, and calcium carbonate. A method of manufacturing the article and kits comprising the article are also described.

The invention discloses a method for recycling phosphorus resources in disodium hydrogen phosphate process iron phosphate mother liquor, which comprises the following steps: enabling the disodium hydrogen phosphate process iron phosphate mother liquor to flow into an oxidation reaction kettle through a mother liquor inlet pipe, then enabling phosphoric acid to flow into the oxidation reaction kettle through a phosphoric acid inlet pipe, adjusting the pH value in the oxidation reaction kettle to be 1-1.5, then respectively adding a ferrous sulfate solution and hydrogen peroxide through a ferrous solution inlet pipe and a hydrogen peroxide inlet pipe, synthesizing a crude iron phosphate solution in the oxidation reaction kettle, discharging the crude iron phosphate solution into a first filter through a first discharge pipe, filtering, and applying a crude iron phosphate filter cake to an aging step (an aging kettle); after filtration, first filtrate is discharged into a neutralization adjusting kettle through a first filtrate pipe, and a sodium hydroxide solution is added into the neutralization adjusting kettle through an alkali liquor inlet pipe, so that the pH value in the neutralization adjusting kettle is controlled to be 7-8; a PAM solution is added through a PAM inlet pipe, other metal impurities are removed through precipitation, supernate is used for recovering sodium sulfate in a sodium sulfate recovery process, and the content of impurity metal ions is extremely low.

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

The present disclosure provides aqueous formulations comprising hydrocortisone sodium phosphate and monothioglycerol. In some embodiments, the formulations comprise monobasic sodium phosphate, dibasic sodium phosphate, or disodium EDTA. The present disclosure further provides a method of treating a disease or disorder in a subject by administering the aqueous formulation.

The application belongs to the technical field of veterinary medicine preparation, and particularly discloses a high-stability veterinary florfenicol effervescent granule and a preparation method thereof, and aims to solve the problem that florfenicol is prone to amide bond hydrolysis and racemization degradation in an acid-base environment of the effervescent granule in the prior art. In the application, a core-shell buffer mesocrystal with sodium phosphate dibasic as the core and citric acid as the shell is used as a drug active chemical protection core, and when water is encountered, the outer shell citric acid is instantaneously dissolved to establish a protective pH microenvironment; and a hydrophilic PEG / hydrogenated vegetable oil coated effervescent acid source is used to realize programmed disintegration. The product has outstanding accelerated stability, and the degradation product is less than 0.5% in 30 days, and the process is simple and controllable.

Provided is a paraben-free aqueous pharmaceutical suspension formulation comprising fexofenadine zwitterionic dihydrate Form I of formula (I) and uses thereof. In certain embodiments, the formulation comprises polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.